157 related articles for article (PubMed ID: 28025216)
1. Hydroxychloroquine for the prevention of recurrent cardiovascular events in myocardial infarction patients: rationale and design of the OXI trial.
Hartman O; Kovanen PT; Lehtonen J; Eklund KK; Sinisalo J
Eur Heart J Cardiovasc Pharmacother; 2017 Apr; 3(2):92-97. PubMed ID: 28025216
[TBL] [Abstract][Full Text] [Related]
2. Hydroxychloroquine in patients with inflammatory and erosive osteoarthritis of the hands (OA TREAT): study protocol for a randomized controlled trial.
Detert J; Klaus P; Listing J; Höhne-Zimmer V; Braun T; Wassenberg S; Rau R; Buttgereit F; Burmester GR
Trials; 2014 Oct; 15():412. PubMed ID: 25348033
[TBL] [Abstract][Full Text] [Related]
3. Hydroxychloroquine reduces interleukin-6 levels after myocardial infarction: The randomized, double-blind, placebo-controlled OXI pilot trial.
Ulander L; Tolppanen H; Hartman O; Rissanen TT; Paakkanen R; Kuusisto J; Anttonen O; Nieminen T; Yrjölä J; Ryysy R; Drews T; Utriainen S; Karjalainen P; Anttila I; Nurmi K; Silventoinen K; Koskinen M; Kovanen PT; Lehtonen J; Eklund KK; Sinisalo J
Int J Cardiol; 2021 Aug; 337():21-27. PubMed ID: 33961943
[TBL] [Abstract][Full Text] [Related]
4. The Pharmacological Mechanisms and Therapeutic Activities of Hydroxychloroquine in Rheumatic and Related Diseases.
Hu C; Lu L; Wan JP; Wen C
Curr Med Chem; 2017; 24(20):2241-2249. PubMed ID: 28302011
[TBL] [Abstract][Full Text] [Related]
5. Longterm Hydroxychloroquine Therapy and Low-dose Aspirin May Have an Additive Effectiveness in the Primary Prevention of Cardiovascular Events in Patients with Systemic Lupus Erythematosus.
Fasano S; Pierro L; Pantano I; Iudici M; Valentini G
J Rheumatol; 2017 Jul; 44(7):1032-1038. PubMed ID: 28507183
[TBL] [Abstract][Full Text] [Related]
6. Effects of Hydroxychloroquine in Patients With Cutaneous Lupus Erythematosus: A Multicenter, Double-Blind, Randomized, Parallel-Group Trial.
Yokogawa N; Eto H; Tanikawa A; Ikeda T; Yamamoto K; Takahashi T; Mizukami H; Sato T; Yokota N; Furukawa F
Arthritis Rheumatol; 2017 Apr; 69(4):791-799. PubMed ID: 27992698
[TBL] [Abstract][Full Text] [Related]
7. Rationale and design of the Anti-Xa therapy to lower cardiovascular events in addition to standard therapy in subjects with acute coronary syndrome-thrombolysis in myocardial infarction 51 (ATLAS-ACS 2 TIMI 51) trial: a randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of rivaroxaban in subjects with acute coronary syndrome.
Gibson CM; Mega JL; Burton P; Goto S; Verheugt F; Bode C; Plotnikov A; Sun X; Cook-Bruns N; Braunwald E
Am Heart J; 2011 May; 161(5):815-821.e6. PubMed ID: 21570509
[TBL] [Abstract][Full Text] [Related]
8. Hydroxychloroquine Use and Cardiovascular Events Among Patients With Systemic Lupus Erythematosus and Rheumatoid Arthritis.
Jorge A; Lu N; Choi H; Esdaile JM; Lacaille D; Avina-Zubieta JA
Arthritis Care Res (Hoboken); 2023 Apr; 75(4):743-748. PubMed ID: 34941008
[TBL] [Abstract][Full Text] [Related]
9. Interleukin-1β inhibition and the prevention of recurrent cardiovascular events: rationale and design of the Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS).
Ridker PM; Thuren T; Zalewski A; Libby P
Am Heart J; 2011 Oct; 162(4):597-605. PubMed ID: 21982649
[TBL] [Abstract][Full Text] [Related]
10. Effect of Losmapimod on Cardiovascular Outcomes in Patients Hospitalized With Acute Myocardial Infarction: A Randomized Clinical Trial.
O'Donoghue ML; Glaser R; Cavender MA; Aylward PE; Bonaca MP; Budaj A; Davies RY; Dellborg M; Fox KA; Gutierrez JA; Hamm C; Kiss RG; Kovar F; Kuder JF; Im KA; Lepore JJ; Lopez-Sendon JL; Ophuis TO; Parkhomenko A; Shannon JB; Spinar J; Tanguay JF; Ruda M; Steg PG; Theroux P; Wiviott SD; Laws I; Sabatine MS; Morrow DA;
JAMA; 2016 Apr; 315(15):1591-9. PubMed ID: 27043082
[TBL] [Abstract][Full Text] [Related]
11. Vorapaxar in patients with diabetes mellitus and previous myocardial infarction: findings from the thrombin receptor antagonist in secondary prevention of atherothrombotic ischemic events-TIMI 50 trial.
Cavender MA; Scirica BM; Bonaca MP; Angiolillo DJ; Dalby AJ; Dellborg M; Morais J; Murphy SA; Ophuis TO; Tendera M; Braunwald E; Morrow DA
Circulation; 2015 Mar; 131(12):1047-53. PubMed ID: 25681464
[TBL] [Abstract][Full Text] [Related]
12. Rationale and design of the Cardiovascular Inflammation Reduction Trial: a test of the inflammatory hypothesis of atherothrombosis.
Everett BM; Pradhan AD; Solomon DH; Paynter N; Macfadyen J; Zaharris E; Gupta M; Clearfield M; Libby P; Hasan AA; Glynn RJ; Ridker PM
Am Heart J; 2013 Aug; 166(2):199-207.e15. PubMed ID: 23895801
[TBL] [Abstract][Full Text] [Related]
13. Rationale and design of ApoA-I Event Reducing in Ischemic Syndromes II (AEGIS-II): A phase 3, multicenter, double-blind, randomized, placebo-controlled, parallel-group study to investigate the efficacy and safety of CSL112 in subjects after acute myocardial infarction.
Gibson CM; Kastelein JJP; Phillips AT; Aylward PE; Yee MK; Tendera M; Nicholls SJ; Pocock S; Goodman SG; Alexander JH; Lincoff AM; Bode C; Duffy D; Heise M; Berman G; Mears SJ; Tricoci P; Deckelbaum LI; Steg PG; Ridker P; Mehran R
Am Heart J; 2021 Jan; 231():121-127. PubMed ID: 33065120
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of vorapaxar as approved for clinical use in the United States.
Magnani G; Bonaca MP; Braunwald E; Dalby AJ; Fox KA; Murphy SA; Nicolau JC; Oude Ophuis T; Scirica BM; Spinar J; Theroux P; Morrow DA
J Am Heart Assoc; 2015 Mar; 4(3):e001505. PubMed ID: 25792124
[TBL] [Abstract][Full Text] [Related]
15. Hydroxychloroquine in systemic lupus erythematosus and rheumatoid arthritis and its safety in pregnancy.
Abarientos C; Sperber K; Shapiro DL; Aronow WS; Chao CP; Ash JY
Expert Opin Drug Saf; 2011 Sep; 10(5):705-14. PubMed ID: 21417950
[TBL] [Abstract][Full Text] [Related]
16. Hydroxychloroquine in systemic lupus erythematosus: results of a French multicentre controlled trial (PLUS Study).
Costedoat-Chalumeau N; Galicier L; Aumaître O; Francès C; Le Guern V; Lioté F; Smail A; Limal N; Perard L; Desmurs-Clavel H; Boutin du LT; Asli B; Kahn JE; Pourrat J; Sailler L; Ackermann F; Papo T; Sacré K; Fain O; Stirnemann J; Cacoub P; Jallouli M; Leroux G; Cohen-Bittan J; Tanguy ML; Hulot JS; Lechat P; Musset L; Amoura Z; Piette JC;
Ann Rheum Dis; 2013 Nov; 72(11):1786-92. PubMed ID: 23144449
[TBL] [Abstract][Full Text] [Related]
17. Long-term use of hydroxychloroquine reduces antiphospholipid antibodies levels in patients with primary antiphospholipid syndrome.
Nuri E; Taraborelli M; Andreoli L; Tonello M; Gerosa M; Calligaro A; Argolini LM; Kumar R; Pengo V; Meroni PL; Ruffatti A; Tincani A
Immunol Res; 2017 Feb; 65(1):17-24. PubMed ID: 27406736
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of Hydroxychloroquine in Hand Osteoarthritis: A Randomized, Double-Blind, Placebo-Controlled Trial.
Lee W; Ruijgrok L; Boxma-de Klerk B; Kok MR; Kloppenburg M; Gerards A; Huisman M; Hazes M; de Sonnaville P; Grillet B; Weel A; Basoski N
Arthritis Care Res (Hoboken); 2018 Sep; 70(9):1320-1325. PubMed ID: 29125901
[TBL] [Abstract][Full Text] [Related]
19. Effects of Hydroxychloroquine on endOthelial function in eLDerly with sleep apnea (HOLD): study protocol for a randomized clinical trial.
Tedesco Silva LM; Cortes A; Rossi B; Boll L; Waclawovsky G; Eibel B; Cadaval Gonçalves S; Irigoyen MC; Martinez D
Trials; 2021 Sep; 22(1):638. PubMed ID: 34535165
[TBL] [Abstract][Full Text] [Related]
20. The effect of low-dose colchicine in patients with stable coronary artery disease: The LoDoCo2 trial rationale, design, and baseline characteristics.
Nidorf SM; Fiolet ATL; Eikelboom JW; Schut A; Opstal TSJ; Bax WA; Budgeon CA; Tijssen JGP; Mosterd A; Cornel JH; Thompson PL;
Am Heart J; 2019 Dec; 218():46-56. PubMed ID: 31706144
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
